The FDA granted breakthrough device designation to the Haystack MRD test, which uses ctDNA to detect residual or recurrent ...

CEO Chad Robins highlighted a strong year for Adaptive Biotechnologies, with MRD revenue increasing by 42% year-over-year. Key drivers included a higher gapfill rate of $2,007 for the clonoSEQ test ...

Personalis' mission, since it was founded in 2011, is to transform the active management of cancer through breakthrough ...

MRD refers to cancer cells remaining post-treatment, undetectable by standard imaging, indicating potential recurrence risk. MRD testing methods include flow cytometry and genetic tests, offering ...

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced The Lancet Oncology published a study highlighting the performance of Myriad’s ...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced new data from an AstraZeneca phase 3 clinical trial in lung cancer (NeoADAURA). The findings ...

This marks the first-ever inclusion of ctDNA-MRD testing in these guidelines, representing a significant advancement in lymphoma patient care. "This milestone represents a transformative moment in ...

Minimal residual disease (MRD) has emerged as a significant marker in the treatment of multiple myeloma (MM), allowing ...

This segment explores how minimal residual disease (MRD) status influences treatment decisions following transplant and discusses strategies for integrating MRD-guided approaches into clinical ...

DUBLIN--(BUSINESS WIRE)--The "Minimal Residual Disease Testing Market Size, Share, Forecast, & Trends Analysis By Offering, Technology, Application Sample - Global Forecast to 2031" report has been ...

CEO Chad M. Robins highlighted "strong execution with outperformance on both the top and bottom line" and confirmed the company is "tracking ahead of schedule on key milestones for the year." He ...